Moderna has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19.
There has been a lot of media attention on COVID-19, and alongside valuable reporting there have also been myths and false facts spread through social media and other channels, so what are the key facts about this coronavirus?
The media are uniquely placed to impact what the public think and feel. During outbreaks what challenges are facing journalists? Editor, Martha Powell, asks how we can ensure we’re undertaking reporting responsibly?
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
Discover the latest information on 2019-nCoV including the current knowledge on its transmissibility, origin and clinical features.
A new study in The Lancet has suggested that the novel coronavirus was most genetically similar to two SARS-like coronaviruses of bat origin, but that there may be the possibility of another animal host acting as an intermediate host between bats and humans.
The WHO has declared that the COVID-19 outbreak can be characterized as a pandemic as new cases are reported globally, including a huge spike in cases in South Korea, Italy and Iran and over 100 other countries reporting cases.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
In this interview we speak to Vineet Menachery about his recent talk at the Microbiology Society’s Annual Conference (8–11 April, Belfast, UK) suggesting that CoV emergence is more complicated than receptor binding alone.